The US Food and Drug Administration approved Boehringer Ingelheim’s nerandomilast, marketed as Jascayd, for idiopathic pulmonary fibrosis (IPF), the first new approval in the indication in over ten years. Jascayd is an oral, twice‑daily preferential PDE4B inhibitor that slowed lung‑function decline versus placebo in a pivotal study published in the New England Journal of Medicine. Regulators granted a priority review and the approval expands treatment options for a disease with limited therapeutic advances. Analysts characterized Jascayd as a modest but material step forward given the tolerability and incremental efficacy profile compared with existing antifibrotics. Boehringer plans to position Jascayd alongside its established IPF franchise and will provide data to payers and clinicians as uptake begins. The approval also underscores ongoing investor and R&D interest in targeting inflammation and fibrosis pathways in chronic lung disease.